AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes  by Mallett, Corey P. et al.
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a  b  s  t  r  a  c  t
Avian  H7  is  one  of several  inﬂuenza  A virus  subtypes  that  have  the  potential  to cause  pandemics.  Herein
we  describe  preclinical  results  following  administration  of  an  investigational  H7N1  inactivated  detergent-
split  virion  vaccine  adjuvanted  with  the AS03  Adjuvant  System.  The  adjuvanted  H7N1  vaccine  was  highly
immunogenic  compared  to the  non-adjuvanted  H7N1  vaccine  in unprimed  mice  with  less  than  100  ng
of hemagglutinin  antigen  per dose.  In addition,  compared  to  the  non-adjuvanted  vaccine,  the  AS03-eywords:
vian H7 subtype inﬂuenza viruses
7N1inﬂuenza vaccine
S03 Adjuvant System
nprimed mouse immunogenicity model
adjuvanted  H7N1  vaccine  also  induced  robust HI and  VN  antibody  responses  that  cross-reacted  with
other  H7  subtypes,  including  recently  emerged  H7N9  virus.  These  H7  data  from  the preclinical  mouse
model  add  to the  existing  H5  data  to suggest  that  AS03  adjuvant  technology  may  be generally  effective
for  formulating  antigen-sparing  detergent-split  virion  vaccines  against  intrinsically  sub-immunogenic
avian  inﬂuenza  A  virus  subtypes.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-NDLow pathogenic H7 inﬂuenza viruses circulate in wild birds
hroughout the world, sporadically are introduced into domestic
oultry populations, and typically cause sub-clinical infections that
an be difﬁcult to detect and monitor [1–3]. Prior to 2013, both
ow pathogenic and highly pathogenic avian H7 inﬂuenza viruses
aused sporadic human infections in Europe and the Americas,
rimarily in persons exposed to poultry [4–9]. In 2003, a large out-
reak of human disease caused by highly pathogenic H7N7 virus
ccurred in the Netherlands [5,6]. Although most infections were
ild, there was a single fatality. Sustained human-to-human trans-
ission of H7 subtype viruses has not been reported, but some
Abbreviations: HA, hemagglutinin; NA, neuraminidase; HI, hemagglutination
nhibition; VN, virus neutralization; GMT, geometric mean titers; AS03, Adjuvant
ystem 03; SRID, single radial immunodiffusion; NIBSC, National Institute for Bio-
ogical Standards and Control.
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H7 viruses exhibit enhanced transmissibility in mammalian mod-
els [10]. More recently, in February 2013, human inﬂuenza cases
caused by a novel low pathogenic H7N9 virus were reported in the
Anhui and Shanghai regions of eastern China [11,12]. By mid-May
2015, the total number of H7N9 cases has exceeded 650 and in
addition to the cases in China, isolated cases have been identiﬁed
in Taiwan, Malaysia, and Canada. Consistent with the epidemiol-
ogy in humans where sustained human-to-human transmission
has not been reported [13], H7N9 viruses have demonstrated a
limited ability to transmit through respiratory droplets in the ferret
transmission model [14,15] suggesting additional genetic changes
are needed for the virus to fully adapt to humans. However, since
H7N9 viruses continue to circulate in domestic poultry in China,
and additional human cases are likely to occur, the pandemic risk
posed by H7N9 viruses has heightened the need for highly effective
H7 subtype vaccines.
Previous attempts to develop H7 subtype vaccines as part of
pandemic preparedness programs have met  with mixed success.
Adjuvanted and non-adjuvanted inactivated H7 vaccines were
poorly immunogenic in Phase I testing even with relatively high
quantities of HA antigen [16,17]. More recently, live attenuated H7
subtype vaccines [18–20] as well as adjuvanted VLP and inactivated
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Study treatment schedule. On study day 0, mice were bled (pre-immunization
baseline) and then immunized with either the H7N1 or the H5N1 vaccine (immu-
nization I). On study day 21, mice were bled (post-I immunization) and then
immunized with the respective vaccine a second time (immunization II). On study
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Fig. 2. Serum hemagglutination inhibition (HI) antibody titers in mice immunized with
the H7N1 vaccine (plus/minus indicated adjuvant) or the H5N1 vaccine (plus/minus
indicated adjuvant). HI titers for each treatment group are expressed as reciprocal
geometric mean titers ± 95% conﬁdence intervals post-I immunization (study day
21) and post-II immunization (study day 35). HI assays were performed as described
in  the Supplementary Methods using H7N1 or H5N1 detergent-split vaccine anti-
gen,  0.5% horse erythrocytes, with 2 hrs of incubation of virus/erythrocyte mixtures.
Numbers on X-axis indicate micrograms of estimated HA (H7N1 vaccine) or actual
HA  (H5N1 vaccine). No antibody titers (HI titers < 20) were detected in the PBS con-
trol  mice (data not shown). * P < 0.0001 [H7N1 (1.5 g estimated HA) with AS03A
vs. H7N1 (1.5 g estimated HA) without AS03A]. ** P > 0.05 [H7N1 (0.375 g esti-ay  35, mice were bled (post-II immunization) a ﬁnal time. Serum HI antibody titers
o the homologous H7N1 or H5N1 vaccine antigens were measured post-I and post-II
mmunization to determine the boosting effect of the respective vaccine.
7 subtype vaccines were generally well-tolerated in early clinical
esting [21,22], and the adjuvanted inactivated vaccine achieved
igher immunogenicity with relatively lower quantities of HA than
he previous H7 subtype inactivated vaccines.
We  have undertaken early development of an investiga-
ional H7N1 inactivated detergent-split virion vaccine adjuvanted
ith the oil-in-water emulsion AS03 Adjuvant System (hereafter
eferred to as AS03) that can serve as a model for H7 subtype,
ncluding H7N9, vaccine development. In the current studies in
ice, we demonstrated that the AS03-adjuvanted H7N1 vaccine
as highly immunogenic with an antigen-sparing effect. This H7N1
accine performed similarly to a licensed AS03-adjuvanted H5N1
nactivated detergent-split virion vaccine which was included as a
omparator in the current studies. In addition, the AS03-adjuvanted
7N1 vaccine induced robust serum antibody responses against
ther H7 viruses from both the Eurasian and North American lin-
ages, including the recently emerged H7N9 virus as well as highly
athogenic H7N7 and H7N3 viruses. These H7 data from the pre-
linical mouse model add to the existing H5 data to suggest that
S03 adjuvant technology may  be generally effective for formulat-
ng antigen-sparing detergent-split virion vaccines against intrinsi-
ally sub-immunogenic avian inﬂuenza A virus subtypes that have
istorically presented several challenges to vaccine development.
Mice were serially immunized with the investigational H7N1
accine or the comparator H5N1 vaccine and bled according to
he schedule described in Fig. 1. Serum antibody responses were
easured by hemagglutination inhibition and viral neutralization
ssays to the vaccine strain as well as additional H7 strains. The vac-
ines, viruses, animal procedures, immuno assays, and statistical
nalysis are described in detail in the Supplementary Methods.
Mice were dosed with the investigational H7N1 vaccine based
n estimated HA content using an HA:total protein ratio of 1:3
hich translated to a bulk vaccine concentration of 100.4 g
A/mL. Estimating the HA dose was necessary since the SRID anti-
en reference reagent calibration from NIBSC was unavailable at the
ime of study initiation. After the reagent calibration was issued,
he actual HA content of the vaccine lot used in this study was
etermined to be 129.0 g HA/mL after 30 months of storage at
–8 ◦C, which is 29% higher than the estimated HA content. The
nderestimation of the HA content in the investigational H7N1
accine resulted in exceeding the targeted HA dosage used in the
urrent study. However, the impact of this was not considered to be
echnically or biologically signiﬁcant as the difference between the
stimated and actual HA content was within the experimental vari-
bility of the SRID assay and below the sensitivity of the unprimed
ouse immunogenicity model to detect when using AS03 as an
djuvant (unpublished observations).
The reciprocal geometric mean HI titers obtained post-I and
ost-II immunization (Fig. 1) with the H7N1 and H5N1 vaccines
ith and without AS03 are presented in Fig. 2. AS03 has pre-
iously been shown to adjuvant monovalent H3N2 and H5N1
etergent-split virion vaccine antigens effectively in different pre-
linical models including BALB/c mice [23], ferrets [24], and pigs
25], and these models have predicted enhanced immunogenicitymated HA) with AS03A vs. H5N1 (0.375 g actual HA) with AS03A]. *** P > 0.05 [H7N1
(1.5  g estimated HA) without AS03A vs. H5N1 (1.5 g actual HA) without AS03A].
in humans. The post-I immunization HI titers were collected for
informational purposes, whereas the post-II immunization HI titers
were considered the deﬁnitive antibody endpoint, as the investi-
gational H7N1 vaccine was  anticipated to be a two-dose vaccine
regimen in humans that will most likely be immunologically naïve
to H7 viruses. The H7N1 vaccine was highly immunogenic across
a broad range of antigen doses tested (5 to 0.023 g estimated
HA) when adjuvanted with AS03A or AS03B after both the ﬁrst
and second immunization. However, the magnitude of the HI titers
increased substantially following the second immunization, thus
demonstrating a strong boosting effect. Comparable immunogenic-
ity has been achieved in unprimed mice with AS03-adjuvanted
monovalent detergent-split virion vaccines produced from other
avian subtypes, e.g., H7N9, down to a vaccine antigen level of
0.0015 g HA (manuscript in preparation). Thus, AS03A and AS03B
are able to adjuvant immune responses down to very low levels
of vaccine antigen, thereby demonstrating antigen dose-sparing
properties that could be critical in a pandemic setting where global
vaccine demand could exceed global vaccine supply. Post-I and
post-II immunization HI titers elicited by the AS03A-adjuvanted
H7N1 vaccine were very close to the titers elicited by the AS03A-
adjuvanted H5N1 vaccine when both vaccines were administered
at comparable dosages (P > 0.05). A vaccine dose–response trend
was observed post-I immunization when the H7N1 vaccine was
adjuvanted with AS03A or AS03B, whereas a more shallow vaccine
dose–response trend was  observed post-II immunization when
the H7N1 vaccine was  adjuvanted with AS03A only. Interestingly,
100% of mice were responders (HI titer > 40) in all adjuvanted
(AS03A and AS03B) vaccine groups post-I and post-II immuniza-
tion when immunized with H7N1 vaccine levels as low as 0.023 g
estimated HA. Conversely, the non-adjuvanted H7N1 vaccine was
poorly immunogenic post-I and post-II immunization compared
to the AS03A-adjuvanted H7N1 vaccine when tested at the same
dosage (1.5 g estimated HA), thus indicating a strong adju-
vant effect (P < 0.0001). Indeed, 79% and 43% of the mice were
non-responders (HI titer < 40) post-I immunization and post-II
immunization, respectively, following immunization with the non-
adjuvanted H7N1 vaccine, and HI titers post-I immunization (HI
GMT  = 16) and post-II immunization (HI GMT = 56) were low. The
3786 C.P. Mallett et al. / Vaccine 33 (2015) 3784–3787
Table 1
Anti-H7 hemagglutination inhibition (HI) and viral neutralization (VN) antibody titers in mouse sera following immunization with the H7N1/AS03A vaccinea.
Virus Strain Anti-H7N1/AS03A high
dose pool
Anti-H7N1/AS03A medium
dose pool
Anti-H7N1/AS03A low dose
pool
PBS placebo pool
HI VN HI VN HI VN HI VN
H7N9b 320 320 320 640 160 320 <10 10
H7N7c 160 NDe 160 ND 80 ND <10 ND
H7N3  (EA)d 320 2560 320 2560 160 1280 <10 <10
H7N3  (NA1)e 320 ND 320 ND 160 ND <10 ND
H7N3  (NA2)f 320 ND 320 ND 160 ND <10 ND
a Serum pools were prepared from post-II immunization (study day 35) sera and HI and VN assays were performed as described in the Supplementary Methods (HI  was
performed using the respective wild-type virus, 1% horse erythrocytes, with 1 hr of incubation of virus/erythrocyte mixtures). Each HI and VN titer reported is the reciprocal
titer  and is the average of two replicates.
b H7N9: A/Anhui/1/2013 (Eurasian lineage/low pathogenic).
c H7N7: A/Netherlands/219/2003 (Eurasian lineage/highly pathogenic).
d H7N3 (EA): A/mallard/Netherlands/12/2000 (Eurasian lineage/low pathogenic).
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hH7N3 (NA1): A/chicken/British Columbia/CN-6/2004 (North American lineage/l
f H7N3 (NA2): A/Mexico/InDRE7218/2012 (North American lineage/highly patho
ND: not determined.
on-adjuvanted H7N1 vaccine at a level of 1.5 g estimated HA
nduced lower HI titers compared to 0.023 g estimated HA of the
7N1 vaccine adjuvanted with AS03A or AS03B. However, these
esults are based on a single non-adjuvanted H7N1 vaccine anti-
en dosage of 1.5 g estimated HA, and it is possible that a higher
osage would have induced a stronger HI antibody response. It is
orth noting the magnitude of the HI response (P > 0.05) as well as
he percentage of non-responders (HI titer < 40) following immu-
ization with the non-adjuvanted H5N1 vaccine (100% of mice
ost-I immunization and 86% of mice post-II immunization) were
imilar to the results for the non-adjuvanted H7N1 vaccine when
dministered at a comparable vaccine antigen dosage, thus con-
rming a strong adjuvant effect for the H5N1 vaccine.
Following the outbreak of H7N9 cases during 2013, there was
nterest in testing the antisera from the current study for broadly
eactive HI and VN antibodies that could potentially cross-react
gainst the emerged H7N9 virus as well as additional H7 subtypes
uch as highly pathogenic H7N7 and H7N3 viruses. Based on the
ange of the adjuvanted H7N1 vaccine antigen dosages that were
dministered, three post-II immunization antisera pools (high,
edium, and low) were selected for these experiments to mini-
ize variability in the antibody responses in the individual serum
amples. As can be seen in Table 1, robust broadly-reactive anti-
ody titers were detected against H7 viruses from both the Eurasian
nd North American lineages, including the recently emerged
7N9 virus (Eurasian lineage) as well as highly pathogenic H7N7
Eurasian lineage) and H7N3 (North American lineage) viruses.
I titers to H7N9, H7N7, and two North American H7N3 viruses
ere very comparable (within 2-fold) to the titers measured
gainst the Eurasian H7N3 virus which has an identical HA to the
7N1 vaccine virus (i.e., HA gene in H7N1 vaccine virus is from
/mallard/Netherlands/12/2000; see Supplementary Methods). A
ecently published phylogenetic tree of H7 viruses demonstrates
he percentage of similarity between the viruses used in this
tudy representing the two lineages [26]. Linear sequence align-
ent demonstrated that there is 97.14% identity at the amino
cid level between the HA of the H7N3 virus of the Eurasian lin-
age (A/mallard/Netherlands/12/2000) and the H7N9 virus also of
he Eurasian lineage (A/Anhui/1/2013), which provides some ratio-
ale for the observed cross-reactivity (sequence alignment data not
hown). Of the sixteen amino acid differences in the HA of the two
iruses, only seven are solvent exposed (as deﬁned by >30% sol-
ent accessibility) using solvent accessibility analysis based on the
hree-dimensional structure, and therefore are likely to be involved
n antigen/antibody interaction (unpublished observations). On the
ther hand, the VN titers to the H7N3 virus were substantially
igher (4- to 8-fold) than the titers to the H7N9 virus, which may,thogenic).
).
in part, be explained by the fact that the VN assay may detect a
broader range of antibodies that target the HA compared with the
HI assay. However, VN titers of 320 to 640 to the H7N9 virus were
still considered to be robust. Interestingly, there was  little to no
difference in the antibody titers between the serum pools regard-
less of the H7 virus or the antibody assay utilized, even though
the serum pools represented a 250-fold vaccine antigen dose range
between the high dose pool and the low dose pool. The demonstra-
tion that the adjuvanted H7N1 vaccine was able to elicit serum
antibody responses that cross-reacted with the H7N9 virus and
other H7 viruses is consistent with recent preclinical and clinical
data that H7N3 and H7N7 live attenuated vaccines elicited HI and
VN antibody responses against emerged H7N9 [19,20,27]. Our data
is also consistent with data of Krammer and colleagues [26] that
have shown at both the preclinical and clinical levels that diver-
gent H7 vaccines elicited cross-reactive serum antibody responses
to H7N9 viruses, and these antibody responses cross-protected
against H7N9 viral challenge at the preclinical level.
Conclusion
The investigational H7N1 vaccine assessed in the current
preclinical study in a mouse model was highly immunogenic
(i.e., robust HI titers in a dose–responsive manner down to
nanogram levels of HA antigen) when formulated with AS03A or
AS03B. Conversely, the non-adjuvanted H7N1 vaccine was  poorly
immunogenic, which demonstrated the requirement of AS03 to
induce robust HI titers. This immunogenicity proﬁle highlighted
by the adjuvant requirement was similar to that of a licensed
H5N1 vaccine in the unprimed mouse model. Finally, the AS03A-
adjuvanted H7N1 vaccine also elicited antibody responses that
cross-reacted with a diverse panel of H7 viruses from both the
Eurasian and North American lineages, including the recently
emerged H7N9 virus as well as highly pathogenic H7N7 and H7N3
viruses. These H7 data add to the existing H5 data to suggest
that AS03 adjuvant technology may  be generally effective for for-
mulating antigen-sparing detergent-split virion vaccines against
intrinsically sub-immunogenic avian inﬂuenza A virus subtypes,
and clinical trials are currently underway to assess the immuno-
genicity of the AS03-adjuvanted H7N1 vaccine in humans.
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